Abstract | OBJECTIVES: METHODS: The participants had localized PDAC with contact or invasion to major arteries. They received GnP on days 1, 15, 29, and 43. The dose of gemcitabine was fixed at 600 mg/m2, whereas that of nab-paclitaxel was at 3 dose levels in accordance with a standard 3 + 3 dose escalation scheme. Three-dimensional radiotherapy was administered concurrently to a total dose of 50.4 Gy per 28 fractions. RESULTS: CONCLUSIONS:
|
Authors | Aoi Hayasaki, Masashi Kishiwada, Yasuhiro Murata, Haruna Komatsubara, Yuki Nakagawa, Koki Maeda, Toru Shinkai, Daisuke Noguchi, Kazuyuki Gyoten, Takehiro Fujii, Yusuke Iizawa, Akihiro Tanemura, Naohisa Kuriyama, Hiroyuki Sakurai, Shuji Isaji, Shugo Mizuno |
Journal | Pancreas
(Pancreas)
Vol. 50
Issue 8
Pg. 1230-1235
(09 01 2021)
ISSN: 1536-4828 [Electronic] United States |
PMID | 34714288
(Publication Type: Clinical Trial, Phase I, Journal Article)
|
Copyright | Copyright © 2021 Wolters Kluwer Health, Inc. All rights reserved. |
Chemical References |
- 130-nm albumin-bound paclitaxel
- Albumins
- Deoxycytidine
- Paclitaxel
- Gemcitabine
|
Topics |
- Aged
- Aged, 80 and over
- Albumins
(administration & dosage)
- Arteries
(pathology)
- Carcinoma, Pancreatic Ductal
(pathology, surgery, therapy)
- Chemoradiotherapy
(methods)
- Deoxycytidine
(administration & dosage, analogs & derivatives)
- Feasibility Studies
- Female
- Humans
- Male
- Middle Aged
- Neoplasm Invasiveness
- Paclitaxel
(administration & dosage)
- Pancreatectomy
- Pancreatic Neoplasms
(pathology, surgery, therapy)
- Vascular Neoplasms
(pathology, surgery, therapy)
- Gemcitabine
|